Vaxcyte's CFO Sells Shares Worth $530,000

Andrew Guggenhime, the President and CFO of Vaxcyte, Inc. (NasdaqGS: PCVX), sold 10,000 shares of the company on June 18, 2026. The shares were sold at an average price of $53.00 each, amounting to a total transaction value of $530,000. This sale was conducted under a planned transaction.

Insider Buying and Selling at Vaxcyte, Inc.

Alongside Andrew Guggenhime's planned sale, other insider transactions were reported on the same date. Grant Pickering, the CEO of Vaxcyte, sold 23,461 shares at an average price of $52.50 under a planned transaction as well. Additionally, Pickering made an unplanned purchase of 225 shares, while Guggenhime also executed an unplanned purchase of 10,000 shares at a price of $5.35 each.

Other Institutional Activity in Vaxcyte

Several institutional investors have also been active in Vaxcyte. Janus Henderson Group PLC increased its holdings by 3,188,687 shares, bringing its total to 16,575,875 shares valued at about $960.2 million. FMR LLC added 2,658,347 shares, ending with 16,492,861 shares worth around $958.4 million. T. Rowe Price Investment Management, Inc. grew its position by 829,684 shares, totaling 12,126,017 shares valued at approximately $704.6 million. RA Capital Management, L.P. and BlackRock, Inc. also increased their stakes by 750,000 and 725,438 shares, respectively.

Vaxcyte Stock Snapshot

Shares of Vaxcyte, Inc. traded at $50.67 recently. The company has a market capitalization of approximately $7.32 billion and a beta of 1.242, indicating its volatility relative to the market. Vaxcyte's stock has seen a 52-week low of $29.08 and a high of $65.00, with moving averages of $53.89 over 50 days and $48.95 over 200 days. The company maintains a strong liquidity position with a current ratio of 7.49 and a quick ratio of 7.18.

Analysts Set New Price Targets

Analysts have been optimistic about Vaxcyte's prospects. On February 26, 2026, BTIG maintained its buy rating with a price target of $89.00. Earlier, on February 2, 2026, Guggenheim reiterated its buy rating with a target of $116.00. Overall, the consensus among nine analysts is a strong buy, with a mean target price of $109.00.

About Vaxcyte

Vaxcyte, Inc., based in San Carlos, California, is a clinical-stage biotechnology company focused on developing vaccines to combat bacterial infectious diseases. The company's lead candidate, VAX-24, is designed to prevent invasive pneumococcal disease in infants. Vaxcyte also works on other vaccine candidates targeting diseases such as Group A Streptococcus and periodontitis. Founded in 2013, Vaxcyte continues to innovate in the healthcare sector under the leadership of CEO Grant E. Pickering.

Bottom Line

Andrew Guggenhime's sale of Vaxcyte shares is part of a planned transaction, reflecting typical insider activity. Vaxcyte, Inc. remains a company of interest to investors due to its ongoing vaccine development efforts and strong institutional support. Analyst ratings suggest confidence in its future performance, with a strong buy consensus and a significant mean price target. As with all 13F filings and insider transactions, these activities are retrospective and may not reflect the current position.